Biospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with Cellulite

BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite

LYNBROOK, N.Y., Nov. 17, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and... More